Northland Securities began coverage on shares of BioLife Solutions (NASDAQ:BLFS) in a research report sent to investors on Monday, The Fly reports. The firm issued an outperform rating on the medical equipment provider’s stock.
Separately, Maxim Group set a $8.00 target price on BioLife Solutions and gave the company a buy rating in a research note on Thursday, January 4th.
Shares of BioLife Solutions (NASDAQ BLFS) opened at $5.14 on Monday. BioLife Solutions has a 12 month low of $1.95 and a 12 month high of $7.53.
In other news, CEO Michael Rice sold 12,540 shares of the firm’s stock in a transaction on Tuesday, January 16th. The stock was sold at an average price of $5.57, for a total value of $69,847.80. Following the completion of the sale, the chief executive officer now directly owns 152,057 shares in the company, valued at $846,957.49. The sale was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 36.80% of the company’s stock.
A number of hedge funds have recently made changes to their positions in the stock. Essex Investment Management Co. LLC increased its position in BioLife Solutions by 199.8% in the fourth quarter. Essex Investment Management Co. LLC now owns 254,096 shares of the medical equipment provider’s stock worth $1,525,000 after purchasing an additional 169,341 shares during the period. Granite Investment Partners LLC acquired a new stake in BioLife Solutions in the third quarter worth about $1,205,000. Millennium Management LLC increased its position in BioLife Solutions by 901.6% in the fourth quarter. Millennium Management LLC now owns 182,550 shares of the medical equipment provider’s stock worth $1,095,000 after purchasing an additional 164,324 shares during the period. EAM Investors LLC acquired a new stake in BioLife Solutions in the third quarter worth about $555,000. Finally, Wells Fargo & Company MN acquired a new stake in BioLife Solutions in the fourth quarter worth about $111,000. Hedge funds and other institutional investors own 12.19% of the company’s stock.
About BioLife Solutions
BioLife Solutions, Inc (BioLife) is engaged in the developing, manufacturing and marketing a portfolio of biopreservation tools and services for cells, tissues and organs, including clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold chain management application for shippers.
Receive News & Ratings for BioLife Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions and related companies with MarketBeat.com's FREE daily email newsletter.